news, journals and articles from all over the world.
Millions around the world have waited for news about a COVID-19 vaccine, regarding it as the beginning of the end for the global pandemic and a herald for the eventual return to “normal life.” Recent announcements from pharmaceutical companies Pfizer and Moderna that their respective late-stage vaccine trials have shown a 90% or better effectiveness rate have received international applause, excitement furthered with estimates that doses could be ready as early as December.
Researchers at the University of Alberta say a protease in SARS-CoV-2 can be targeted with a drug that is also used to treat feline infectious peritonitis, a fatal infection in cats caused by a coronavirus. The drugs, dipeptide-based protein inhibitors, could be used to slow or stop replication of the COVID-19 virus in humans. During the 70th annual meeting of the American Crystallographic Association, Joanne Lemieux will outline how the drugs are strong candidates for the treatment of human coronavirus infections.
As the global response to the SARS-COV-2 virus that causes COVID-19 approaches 200 days, Baylor Scott & White Research Institute, the research and development arm of Baylor Scott & White Health, is accelerating its pace of bringing clinical trials online.
Baylor Scott & White Research Institute continues to mobilize staff and resources, including components needed to integrate critical patient-safety measures at every participating site within the Baylor Scott & White system for industry sponsored drug trials, investigator-initiated drug trials and research studies, and observational and data studies designed to help increase knowledge around case trends, viral epidemiology, and care best practices.
The Baudry Lab at The University of Alabama in Huntsville (UAH) has identified 125 naturally occurring compounds that have a computational potential for efficacy against the COVID-19 virus from the first batch of 50,000 rapidly assessed by a supercomputer.
For the first time, surgeons at Northwestern Medicine performed a double-lung transplant on a patient whose lungs were damaged by COVID-19. The patient, a Hispanic woman in her 20s, spent six weeks in the COVID ICU on a ventilator and extracorporeal membrane oxygenation (ECMO), a life support machine that does the work of the heart and lungs.
The AIDS Clinical Trials Group (ACTG) has initiated a clinical trial to evaluate whether the drug combination hydroxychloroquine and azithromycin can prevent hospitalization and death from COVID-19.
University of Alabama in Huntsville (UAH) professor of biological science Dr. Jerome Baudry is collaborating with Hewlett Packard Enterprise (HPE) to use HPE’s Cray Sentinel supercomputer to search for natural products that are effective against the COVID-19 virus.
English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu